XL
Xilio Therapeutics, Inc.
XLO · NASDAQ
$9.13 +0.55% (+$0.05)
1M -0.65%
Market Cap $60.0M
P/E Ratio -
Div. Yield -
ROE 50.77%
Bulios Fair Price
$13.42
47.0% upside
Trenutna cena
$9.13
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica XLO trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Weak
3/9Valuation
100 /100
Cheap P/B 0.83x
P/S 0.94x
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 30.63%
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak Net margin 34.06%
Op. margin 48.94%
FCF margin 95.59%
Quality
5 /100
Poor ROE 50.77%
ROA 14.15%
Asset turnover 0.42x
Debt
100 /100
Low Current ratio 4.25x
Debt/Equity 0.09x
Net debt/EBITDA N/A
Stability
47 /100
Moderate EPS volatility 31.16%
Profitable years 0
Beta -0.12x
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o XLO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Rene Russo
Employees
76
Headquarters
Waltham
Prihajajoči dogodki
05 NOV.
Earnings
Upcoming earnings report